Top

Surgery Today

Published in:

01-10-2015 | Original Article

Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3–4 breast cancer patients

Authors: Kenjiro Jimbo, Takayuki Kinoshita, Sota Asaga, Takashi Hojo

Published in: Surgery Today | Issue 10/2015

Abstract

Purpose

The aim of this study was to retrospectively assess the oncological safety of breast-conserving surgery (BCS) after primary systemic chemotherapy (PST) in terms of local recurrence (LR) in cT3–4 patients.

Methods

The subjects were 146 cT1–2 patients who underwent BCS after PST, and 169 patients with cT3–4 primary breast cancer. Of the 169 patients with cT3–4 disease, 20 underwent surgery first, and 149 underwent surgery after PST (mastectomy: 101 patients; BCS: 48 patients). The LR-free survival (LRFS) was analyzed using a Kaplan–Meier analysis. We evaluated the predictors using Cox proportional hazards modeling for LR after PST.

Results

There was no significant difference in 5-year LRFS between the cT1–2 and cT3–4 groups that underwent BCS after PST (98.6 vs. 92.5 %; P = 0.074). The 5-year LRFS was 94.7 % in the group that underwent initial surgery and 93.0 % in the PST group (P = 0.845) in the cT3–4 patients, while the 5-year LRFS rates were 93.2 % in the BCS subgroup and 92.5 % in the mastectomy subgroup (P = 0.958). In a multivariate analysis, the histological type, hormone negativity and a higher histological grade were independent predictors of LR after PST.

Conclusions

BCS after PST may be oncologically acceptable for cT3–4 breast cancers in terms of the LR compared with initial surgery or mastectomy after PST.

Takahashi H, Fujii T, Nakagawa S, Inoue Y, Akashi M, Toh U, et al. Usefulness of breast-conserving surgery for breast cancer. Surg Today. 2013;. doi:10.1007/s00595-013-0767-2.PubMedCentral

Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.CrossRefPubMed

Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10:47–52.CrossRefPubMed

Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat. 1999;58:151–6.CrossRefPubMed

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMed

Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–84.CrossRefPubMed

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.CrossRefPubMed

Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814–9.CrossRefPubMed

Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22:2303–12.CrossRefPubMed

10.

Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer. 2012;118:4385–93.CrossRefPubMed

11.

Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, et al. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006;107:1459–66.CrossRefPubMed

12.

Loibl S, von Minckwitz G, Raab G, Blohmer JU, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434–42.CrossRefPubMed

13.

Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001;19:3828–35.PubMed

14.

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.CrossRefPubMedCentralPubMed

15.

Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, Boughey JC. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol. 2012;19:1153–9.CrossRefPubMed

16.

Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010;103:297–302.CrossRefPubMedCentralPubMed

17.

Cebrecos I, Cordoba O, Deu J, Xercavins J, Rubio IT. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy? Eur J Surg Oncol. 2010;36:528–34.CrossRefPubMed

18.

Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence. Breast J. 2010;16:9–13.CrossRefPubMed

19.

Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110:531–9.CrossRefPubMed

Title: Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3–4 breast cancer patients
Authors: Kenjiro Jimbo
Takayuki Kinoshita
Sota Asaga
Takashi Hojo
Publication date: 01-10-2015
Publisher: Springer Japan
Published in: Surgery Today / Issue 10/2015
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-014-1052-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3–4 breast cancer patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Erratum to: Surgical risk model for acute diffuse peritonitis based on a Japanese nationwide database: an initial report on the surgical and 30-day mortality

Optimal Roux-en-Y reconstruction after distal gastrectomy for early gastric cancer as assessed using the newly developed PGSAS-45 scale

Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

Surgical risk model for acute diffuse peritonitis based on a Japanese nationwide database: an initial report on the surgical and 30-day mortality

Nonoperative management of blunt splenic injury in adults: there is (still) a long way to go. The results of the Bologna-Maggiore Hospital trauma center experience and development of a clinical algorithm

Post-hepatectomy liver failure in patients with colorectal liver metastases